AcceXible is looking for up to €450,000 and expects a turnover of one million in 2021

AcceXible seeks private capital. The Spanish company, specialized in developing a platform for the detection and monitoring of diseases through speech analysis, will open a funding round with which it hopes to get up to $548,000 (€450,000) on the crowdfunding platform Crowdcube. 

The co-founder and CEO of AcceXible, Carla Zaldua, explained that the company will use the funds to accelerate its entry into the European market and strengthen its strategy to reach the United States. The round has the objective of capturing $306,000 (€250,000), but the company expects to capture up to $548,000 (€450,000) and close it in February. 

Carla Zaldua and Javi Zaldua are the co-founders of AcceXible and the majority shareholders, a situation that will continue after the financing round. The company has received $609,000 (€500,000) since its foundation, in mid-2017. The company has obtained $306,000 (€250,000) from the Neotec program, from the Center for the Development of Industrial Technology, and the rest was contributed by Enisa and the partners.  

Read more about AcceXible and find the latest business headlines in the world with the Born2Invest mobile app.

AcceXible forecasts a turnover of one million euros in 2021

The goal of AcceXible is to have a turnover of one million euros in 2021. The company, based in Barcelona Tech City, has recently received the CE mark on its product, which allows it to start marketing its platform in the European Union. Zaldua pointed out that the first markets will be Spain and the United Kingdom. This novelty will allow the company’s platform to be scaled both as a tool for detecting and monitoring diseases. After programming the platform in Spanish and English, the next market 

AcceXible wants to access is France. In Europe, only 20% of people suffering from dementia are diagnosed in early stages. AcceXible’s model allows an early and non-invasive diagnosis and the possibility of monitoring the evolution of the disease remotely. AcceXible will also start in the next weeks a new project with Quirónsalud and another one with the primary care of the public health in Spain. The company also collaborates with the hospital group, the Basque Health Service, the Madrid Salud Cognitive Deterioration Prevention Center and the Oroitu Day Center.  

The company is confident of making the leap to the United States by the end of 2021 or early 2022 The start up plans to make the leap to the United States by the end of 2021 or early 2022 and is closing the first collaboration agreement with a company dedicated to the detection of Alzheimer’s disease through the retina, whose name has not spread, but which has attracted twenty million dollars. 

In addition, the company is negotiating the use of its platform as a screening tool for clinical trials with a pharmaceutical company. AcceXible’s funding round has attracted the interest of investors and players in the pharmaceutical sector. The company is also in discussions with a Spanish group of clinics for a collaboration. Within a year, in 2022, Zaldua advances that “we will open a financing round of $1.84 million (€1.5 million).”

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.